Global Hyaluronic Acid Giant's Fund Investment in Shinesky Biotech
- Chaileedo Press
- Jun 26, 2022
- 3 min read
Chinese supramolecular chemical technology application enterprise Shinesky Biotech secured a Series A funding of nearly 30 million USD, with investment from Hua Yaxilang and others. To this date, Shinesky Biotech has developed proprietary raw materials for Marubi, Fawa Herb Beauty, and other cosmetics enterprises.
On June 24, China Standard Time, Shenzhen Shinesky Biotech Technology Co., Ltd. (hereinafter referred to as "Shinesky Biotech ")secured a Series A funding of nearly 30 million USD. This round of investment is jointly led by Huaxi Longya, Oriental Fortune Capital, with Cowin Capital, Hongtai Aplus, Leaguer Hongxin, Sihai New Materials, etc following suit.
According to CHAILEEDO, Bloomage Langya is a joint industrial investment fund for Bloomage Biotech and Lancygroup centering on investment in Comprehensive Health. ① Bloomage Biotech is the world's leading enterprise in hyaluronic acid research and development, production, and sales, accounting for 43% of the global market share, it boasts functional skin care brands BIOHYALUX, QUADHA, MEDREPAIR, Bio-MESO and so on.
Shinesky Biotech was founded in 2017 and is the first technology industrial platform company in the world to apply supramolecular chemistry technology to the field of pan-health. Based on the supramolecular modification technology, Shinesky Biotech modified various cosmetic active raw materials, reduced the irritation of the raw materials, improved the transdermal absorption rate, and improved their stability. For example, the stability of retinol is improved by encapsulating the retinol with supramolecular molecules. Through the supramolecular encapsulation of blue copper peptide, snake-like peptide, and CONUS peptide, transdermal absorption can be improved.
In April 2021, Shinesky Biotech released cosmetics supramolecular raw materials into the market. After a year of promotion, Shinesky Biotech established a cooperative relationship with dozens of cosmetics, such as Bloomage Biotech, Marubi, Fawa Herb Beauty, Whoo, Simpcare, UNISKIN, Peterson’s Lab, USMILE, SOOCAS, and Monster Code, and respectively developed proprietary raw materials for them.
In the process of deciding the proportion of cosmetics raw materials, the structure of different molecules is different, the structure of the molecules needs repeated tests to reach the structure adaptability of the molecules, therefore the process and the result of the proportion are erratic with relatively low efficiency. The investment of the Shinesky Biotech fund of Bloomage Biotech will help Bloomage Biotech's functional skin care products greatly improve the solubility, stability, irritation, transdermal effect, and efficacy of raw materials. Plus, as a strategic investor of Shinesky Biotech, Bloomage Biotech will also help Shinesky Biotech develop the international cosmetics raw material market and aesthetic medicine market.
Dr. Liang Shuang, head of investment at Bloomage Biotech, comments that supramolecular technology, as a new technology applied in cosmetics and beauty products, can be combined based on existing raw materials to improve catalytic efficiency, product efficiency, and permeability of existing raw materials. At present, supramolecular technology has been applied to glycoside materials, amino acids materials, polypeptide substances, and collagen.
Since the beginning of this year, Syiobio, Winkey Bio, and other companies have secured financing, especially one of China Syiobio's investors PROYA, a Chinese cosmetics giant. CHAILEEDO found that the above-mentioned financing funds are mainly for the research and development of functional skin care products.
Industry insiders note that China's cosmetics and other pan-health industries enjoy large market space with hundreds of billions worth of market size, and average an annual growth rate of more than 10% for quite a long time. Biotechnology has become the core driving force for the skin care and aesthetic medicine sector.
The fact is, Chinese cosmetic enterprises have invested in and distributed synthetic biotechnology and cosmetics materials-related industries because synthetic biology technology is regarded as the future orientation of cosmetics materials production. Synthetic biology technology can not only improve the safety, stability, and biological activity of ingredients and raw materials but also customize such substances according to specific requirements, thereby making efficacy more precise.
The integration of the innovation, performance, and function of cosmetic materials will be the key to propelling China's pan-health industry. It is foreseeable that for some time to come, an increasing number of beauty companies will seek investment in biotech enterprises oriented towards comprehensive health.
Paraphrase:
① Comprehensive Health: a concept centering on people's daily essentials, birth-to-death process, with a focus on various risks and misconceptions that undermines health and an advocate for self-health management. What it pursues is not only an individual's physical health, but also covers the mental, psychological, physical, social, environmental, moral, and other aspects of comprehensive health.
Comments